What Chevron’s overturn means for biopharma

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities. 

The Supreme Court overturned the doctrine in June, bringing significant implications for the healthcare industry and federal regulators like the FDA. 

In this week's episode of "The Top Line," Fierce Pharma’s Kevin Dunleavy chats with Project Farma President Anshul Mangal about the potential impact on the biopharma industry. 

To learn more about the topics in this episode: 

• Supreme Court overrules Chevron deference, dealing blow to federal healthcare agencies
• The Supreme Court just limited federal power. Healthcare is feeling the shock waves
• How Chevron's demise could impact employers, purchasers and health payers

See omnystudio.com/listener for privacy information.